Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: The VLDL-2 study (very large database of lipids)

Journal of the American College of Cardiology

Volumn 62, Issue 21, 2013, Pages 1960-1965

  Elshazly, Mohamed B ^a,b   Martin, Seth S ^b   Blaha, Michael J ^b   Joshi, Parag H ^b   Toth, Peter P ^c,d   McEvoy, John W ^b   Al Hijji, Mohammed A ^b   Kulkarni, Krishnaji R ^e   Kwiterovich, Peter O ^b   Blumenthal, Roger S ^b   Jones, Steven R ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e Atherotech Diagnostics Inc   (United States)

Author keywords

discordance; LDL cholesterol; lipids; non HDL cholesterol; percentiles; secondary prevention

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CENTRIFUGE; CONTROLLED STUDY; DATA BASE; DENSITY GRADIENT CENTRIFUGATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; SECONDARY PREVENTION;

CARDIOVASCULAR DISEASE; CVD; DISCORDANCE; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; LDL CHOLESTEROL; LDL-C; LIPIDS; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; NON-HDL CHOLESTEROL; PERCENTILES; SECONDARY PREVENTION; VAP; VERTICAL AUTO PROFILE; VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL; VLDL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84888211663     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.045     Document Type: Article

References (18)

1. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
2. Nichols M, Townsend N, Luengo-Fernandez R, et al. 2012 European Cardiovascular Disease Statistics. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
4. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
5. Developed with the special contribution of: European Association for Cardiovascular Prevention & Rehabilitation, Authors/Task Force Members Z. Reiner ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
6. J.H. Contois, J.P. McConnell, and A.A. Sethi Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 55 2009 407 419
7. A.D. Sniderman, J. De Graaf, and P. Couture Low-density lipoprotein-lowering strategies Curr Opin Cardiol 27 2012 405 411
8. K.R. Kulkarni Cholesterol profile measurement by vertical auto profile method Clin Lab Med 26 2006 787 802
9. S.S. Martin, M.J. Blaha, and M.B. Elshazly Friedewald estimated versus directly measured low-density lipoprotein cholesterol and treatment implications J Am Coll Cardiol 62 2013 732 739
10. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
11. E.V. Kuklina, P.W. Yoon, and N.L. Keenan Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006 JAMA 302 2009 2104 2110
12. V. Bittner, R. Hardison, and S.F. Kelsey Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 106 2002 2537 2542
13. Y. Cui, R.S. Blumenthal, and J.A. Flaws Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 2001 1413 1419
14. A. Varbo, M. Benn, A. Tybjærg-Hansen, A.B. Jørgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
15. S.M. Boekholdt, B.J. Arsenault, and S. Mora Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
16. A.D. Sniderman, K. Williams, and J.H. Contois A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
17. M. Miller, N.J. Stone, and C. Ballantyne Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
18. C.M. Ballantyne, B. Pitt, J. Loscalzo, V.A. Cain, and J.S. Raichlen Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial) Am J Cardiol 111 2013 506 509